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Abstract
Background: We previously described an endogamous Pakistani kindred in whom we identified a novel homozygous
missense mutation in the PRKCD gene encoding for protein kinase C δ (PKCδ) as a cause of monogenic systemic lupus
erythematosus (SLE). PKCδ has a role in the negative regulation of B cells. Given the nature of the disease, a
logical targeted therapeutic approach in these patients is B cell depletion. Indeed, the 3 siblings all had a marked clinical
response and resolution of symptoms with rituximab, although 2 of the siblings had severe reactions to rituximab thus
precluding further treatment with this. We therefore describe the first successful use of ofatumumab for this rare form of
monogenic SLE.
Case presentation: All three affected siblings presented with SLE before the age of 3-years with lethargy, intermittent
fever, thrombocytopenia, cutaneous involvement, alopecia, and hepatosplenomegaly. Tubulointerstitial nephritis was also
present in 1 of the siblings. Homozygosity mapping followed by whole exome sequencing identified a homozygous
missense mutation in PRKCD (p.Gly432Trp), subsequently confirmed by Sanger sequencing to be present in all 3 siblings.
All 3 patients were initially treated with rituximab, however 2 of the siblings developed severe infusion-related reactions.
For subsequent disease flare in these individuals we therefore used an alternative B cell depleting agent, ofatumumab
(300 mg/1.73m2 on day 1; 700 mg/1.73m2 on day 15). This resulted in marked clinical improvement in both patients. To
the best of our knowledge, this is the first report describing the successful use of ofatumumab for PKCδ deficiency.
Conclusions: PKCδ deficiency causes a monogenic form of SLE which responds well to B cell depletion. Ofatumumab is
also likely to have a therapeutic role for sporadic juvenile SLE (jSLE) patients intolerant of rituximab.
Keywords: Ofatumumab, Juvenile SLE, Rituximab, Protein kinase C δ deficiency, Acute tubulointerstitial nephritis
Background
Juvenile SLE (jSLE) is rare before 5 years of age and can
present with severe and atypical disease. There is an
ever-expanding list of monogenic causes described, with
a range of cutaneous and systemic features including
cold-induced chilblain lupus, or mucocutaneous involve-
ment, through to severe systemic and organ threatening
manifestations such as renal involvement [1]. Awareness
of monogenic forms of SLE is important, particularly for
patients who present with SLE early in life. Moreover,
there may be more targeted therapeutic options for such
patients as compared to standard treatments for sporadic
SLE [2]. The complexity in identifying a monogenic cause
of lupus highlights the diagnostic importance of next
generation sequencing (NGS) in this context, which can
have major therapeutic and prognostic impact, in addition
to facilitating family counselling. Indeed, the conventional
approach of gene-by-gene testing by Sanger sequencing is
increasingly superseded by NGS, particularly since there is
a growing list of monogenic forms of SLE [2, 3].* Correspondence: Lindalei93@gmail.com
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We previously described an endogamous Pakistani
kindred (Fig. 1a), with a homozygous missense mutation
(p.Gly432Trp) in the PRKCD gene which codes for the
active region of protein kinase C δ (PKCδ) as a cause of
monogenic SLE [4]. PRKCD is located on chromosome
3p21.31, and its protein product PKCδ has a role in the
negative regulation of B cells. Mice lacking in PKCδ have
expansion and dysregulation of B cells [5], that might sug-
gest a therapeutic role for B cell depletion in the human
disease caused by PRKCD mutations. Herein we describe
a novel disease manifestation of PKCδ deficiency, acute
tubulointerstitial nephritis (TIN), and successful response
to the B cell depleting agent ofatumumab in two of the sib-
lings who developed hypersensitivity reactions to rituximab.
Case presentation
The pedigree is shown in Fig. 1a. The parents were first
cousins. The first two siblings (II-1 and II-2) became symp-
tomatic at 12 months of age, and II-3 became symptomatic
at 26 months of age. All three affected siblings (II-1, II-2,
and II-3) presented with an SLE-like phenotype (Table 1)
consisting of constitutional symptoms (intermittent fever,
night sweats and fatigue), severe thrombocytopenia, cutane-
ous involvement, scarring alopecia, and hepatosplenome-
galy. The cutaneous involvement in both siblings consisted
of a photosensitive rash starting on the scalp and spreading
to the malar area and nasal bridge with a petechial rash on
the palms, soles, fingers and toes. II-1 also had ulcers on
her palate on an oral examination. II-2 had dilated nailfold
capillaries on the fifth finger of her left hand. II-1 had a
palpable spleen measuring 2-3 cm with palpable cervical
lymphadenopathy (anterior and posterior chains) and in-
guinal lymphadenopathy. II-2 presented with a palpable
liver edge and a palpable spleen measuring 2-3 cm with
cervical and inguinal lymphadenopathy. There was no arth-
ritis in both siblings. There was no abnormality detected in
the cardiac or central nervous system for either II-1 or II-2,
and they were both afebrile. A summary of immunological
and other relevant investigations for all 3 siblings is pro-
vided in Tables 2 and 3. Based on the clinical and patho-
logical results, the siblings fulfilled the classification criteria
for SLE (Table 1). Homozygosity mapping followed by
Fig. 1 Pedigree of the family and renal histology. a The affected siblings (shaded) are homozygous for the PRKCD mutation as indicated and the
parents are carriers of the mutation. WT, wild type. b Low power (Periodic acid–Schiff stain, original magnification × 40) and Fig. 1c higher power
(Haematoxylin and Eosin stain, original magnification × 200) showing severe acute tubulointerstitial nephritis with marked predominantly
mononuclear inflammatory infiltrate and associated mild acute tubular damage
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whole exome sequencing identified a homozygous missense
mutation (p.Gly432Trp) in PRKCD in II-1 and II-2, subse-
quently confirmed by Sanger sequencing to be present in
all 3 siblings (Fig. 1a). Full details regarding the method-
ology for the various gene screening strategies are available
elsewhere [4].
In addition to the investigations included in Tables 1, 2
and 3, additional autoimmune workup in II-1 at the time of
initial presentation revealed: IgA 2.20 G/L (RR 0.4–2.0), tis-
sue transglutaminase (TTG) IgA screening negative, C1q
18.0 U/ml (RR 0–15), C1 esterase inhibitor 438.0 mg/L
(RR 150–350), C1 esterase functional assay > 93% (RR >
84%), C1q level 53.0 mg/L (RR 50–250), proteinase 3 anti-
neutrophil cytoplasmic antibodies (PR3-ANCA) 0.40 IU/ml
(RR 0–1.99), myeloperoxidase (MPO) ANCA 0.40 IU/ml
(RR 0–3.49), rheumatoid factor < 0.20 IU/ml (RR 0. 20),
thyroid peroxidase antibodies < 33.4 IU/ml (RR < 60), clas-
sical and alternative functional complement assays were
normal at 110% (RR > 40) and 92% (RR > 10) respectively.
Full autoimmune workup (see also Tables 1, 2 and 3)
for II-2 revealed: IgA 2.88 G/L (RR 0.4–2.0), TTG IgA
screening negative, C1q 9.0 U/ml (RR 0–15), C1 esterase
inhibitor 434.0 mg/L (RR 150–350), C1 esterase functional
assay > 93% (RR > 84%), C1q level 42.0 mg/L (RR 50–250),
PR3-ANCA 0.60 IU/ml (RR 0–1.99), MPO-ANCA
0.80 IU/ml (RR 0–3.49), rheumatoid factor < 0.20 IU/ml
(RR 0. 20), thyroid peroxidase antibodies < 33.4 IU/ml
(RR < 60), and normal classical and alternative comple-
ment functional pathway assay at 75% (RR > 40) and
99% (RR > 10) respectively.
ENA antibody typing was also done for II-1 and II-2 at
presentation, at time of relapse and at 8 months follow-up
after ofatumumab (Table 2). ASMA and anti-LKM auto-
antibodies were not assessed.
II-1 and II-2 failed initial treatment with high dose
corticosteroids, hydroxychloroquine 5 mg/kg per day and
azathioprine 2 mg/kg per day. II-2 developed spontaneous
gingival bleeding, and platelet-count 4 × 10^9/L (reference
range [RR]150–450). Following IVIG 2 g/kg, platelets rose
transiently to 30 × 10^9/L. Consequently, she received
rituximab (750 mg/m2 (maximum 1 g) on day 1 and
15). The platelet count rapidly normalised (179 × 10^9/
L), with near-normalization of other laboratory param-
eters [6]. However, during the second rituximab infu-
sion she developed urticaria, wheeze, and hypotension
despite premedication, necessitating discontinuation of
the infusion discontinuation, and treatment with hydrocor-
tisone and volume expansion with normal saline. Despite
that, she had a good therapeutic response and adequate B
cell depletion (peripheral blood CD19 count less than 1%).
Table 1 Systemic Lupus International Collaborating Clinics
(SLICC) criteria and the presence (√) or absence (x) for each
affected sibling [25]
II-1 II-2 II-3
Acute cutaneous lupus √ √ √
Chronic cutaneous lupus x x x
Oral or nasal ulcers √ x x
Non-scarring alopecia √ √ √
Arthritis x x x
Serositis x √ x
Renal x √ x
Neurologic x x x
Haemolytic anaemia √ √ √
Leukopenia √ √ x
Thrombocytopenia √ √ √
ANA (above lab range) √ √ √
Anti-dsDNA(above lab range) √ √ √
Anti-Sm x x √
Anti-phospholipid antibody √ √ x
Low complement √ √ √
Direct Coombs’ test not assessed not assessed not assessed
WCC White cell count, ANA Anti-nuclear antibodies, ds-DNA Double-stranded
deoxyribonucleic acid, Sm Smith. To fulfil these classification criteria, 4 or
more criteria must be present (including at least one clinical and one
immunological feature), or biopsy proven lupus nephritis with positive ANA
or anti-DNA antibodies
Table 2 Extractable nuclear antigen (ENA) antibody typing for siblings II-1 and II-2 at initial presentation, at relapse of disease and
8 months after ofatumumab
ENA antibody typing Patient II-1 Patient II-2
At presentation At relapse 8 months after ofatumumab At presentation At relapse 8 months after ofatumumab
anti-NRNP negative negative positive negative negative equivocal
anti-SME negative negative positive negative negative positive
anti-Ro negative negative positive negative negative negative
anti-La negative negative negative negative negative negative
anti-Jo-1 negative negative negative negative negative negative
anti-Scl70 negative negative negative negative negative negative
other ENA antibodies weakly positive negative negative weakly positive negative negative
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Twelve months later, II-2 was re-admitted with lethargy,
poor appetite, night sweats and was found to have renal
impairment, ongoing acute phase response, and return of
B cells (CD19 23.7%): blood pressure 102/43 mm/Hg; urea
7.8 mmol/L (RR 2.5–6.0); creatinine 83 μmol/L (RR 30–
48); and ESR 75 mm/hr. (RR 0.0–10.0). Urinary chemistry
was consistent with tubulopathy: urine (u-) sodium
122 mmol/l, u-potassium 36 mmol/L, u-pH 7.0, u-nitrosami-
noglycan [NAG]/creatinine ratio 67 (RR 2–20), u-albumin/
creatinine ratio 1.1 mg/mmol (RR 0.2–4.5). Renal biopsy
confirmed acute tubulointerstitial nephritis, with coexistent
chronic changes (Fig. 1b, and c). She received IV methyl-
prednisolone (30 mg/kg) for 3 days, thereafter continuing
on a tapering course of prednisolone 40 mg/day. In
view of her genotype and excellent previous therapeutic
response (but severe drug reaction) to rituximab, ofatu-
mumab (300 mg/1.73m2 on day 1; 700 mg/1.73m2 on
day 15) was commenced. Again, B cells depleted suc-
cessfully (CD19: 0.1%), and her lethargy, poor appetite,
and night sweats had resolved completely two weeks
later. At follow-up eight months later, her renal function
had improved (urea 4.1 mmol/L; creatinine 52 μmol/L)
allowing successful prednisolone taper; but tubular func-
tion was not completely normal (u-NAG:creatinine ratio
74), indicating that the chronic changes identified on renal
biopsy may be irreversible, and not amenable to improve-
ment with immunosuppressive treatment. At follow-up
eight months after ofatumumab infusion, B cells were still
Table 3 Laboratory data of siblings II-1 and II-2 at initial presentation, at relapse of disease requiring ofatumumab infusion and at
follow-up 8 months after ofatumumab infusion
Investigations Patient II-1 (reference range) Patient II-2 (reference range)
At presentation At relapse 8 months after
ofatumumab
At presentation At relapse 8 months after
ofatumumab
FBC × 10^12/L (RR 4.00–5.20) 3.88 3.92 4.76 3.6 3.01 5.26
Hb g/L (RR 115–145) 96 102 118 97 73 128
Platelets × 10^9/L (RR 150–450) 85 5 209 13 63 397
WCC × 10^9/L (RR 0.0–10.0) 5.94 6.54 6.58 9.60 2.78 7.83
Lymphocytes × 10^9/L (1.5–7.0) 1.79 1.69 1.65 1.70 0.48 1.86
Neutrophils × 10^9/L (RR 1.5–8.0) 2.17 4.20 1.83 1.01 2.23 4.90
CD 19 lymphocyte subset % 21.0 not assessed 0.0 25.0 23.7 0.5
CD 3 lymphocyte subset % 73.0 not assessed 97.5 65.0 83.0 96.0
CD 16+ CD 56+ lymphocyte subset % 4.0 not assessed 1.7 8.0 5.0 0.7
CD 3+ CD 56+ lymphocyte subset % 0.2 not assessed not assessed 0.2 0.8 not assessed
CD 3+ CD4+ lymphocyte subset % 46.0 not assessed 49.7 32.0 38.0 41.5
CD 3+ CD 8+ lymphocyte subset % 21.0 not assessed 40.6 37.0 37.0 42.2
ESR mm/hr. (RR 0–10) 128 132 50 130 75 1
CRP mg/L (RR < 20) 21 19 < 5 28 21 < 5
Urea 3.4 3.9 3.4 4.8 7.8 4.1
Creatinine umol/L (RR 28–57) 36 25 40 33 83 52
Urine creatinine mmol/L 3.4 1.5 3.5 2.8 1.1 0.5
Urine albumin/creatinine ratio mg/mmol (RR 0.2–4.5) 1.5 5.3 3.1 8.9 1.1 not assessed
Urine NAG/creatinine ratio units/mmol (RR 2–20) not assessed not assessed 4 not assessed 67 74
Urine retinol binding protein ug/L not assessed not assessed 39 not assessed not assessed 161
Urine retinol/creatinine ratio ug/mmol (RR 5–41) not assessed not assessed 11 not assessed not assessed 85
ANA 1:1280 not assessed 1:640 Negative not assessed not assessed
Anti-DNA IU/ml (RR 0–9.9) 65 66 16 43 16 4.8
IgG G/L (RR 5.4–16.1) 16.8 22.3 7.66 21.9 18.5 7.12
IgA G/L (RR 0.5–2.4) 2.19 2.35 1.15 2.69 3.34 1.72
IgM G/L (RR 0.5–1.8) 1.63 1.31 0.35 2.90 2.36 0.86
C3 G/L (RR 0.75–1.65) 0.83 0.41 1.51 0.64 0.91 1.37
C4 G/L (RR 0.14–0.54) 0.10 0.03 0.19 0.08 0.15 0.29
RR Reference range, FBC Full blood count, Hb haemoglobin, WCC White cell count, ESR Erythrocyte sedimentation rate, CRP C reactive protein, NAG
Nitrosaminoglycan, DNA deoxyribonucleic acid
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only gradually recovering (CD19 0.5%) (Table 3). In terms
of the antibodies, anti-dsDNA antibodies was 16 IU/ml
(RR 0–9.9) at the time of relapse and this dropped to
4.8 IU/ml (RR 0–9.9) eight months after ofatumumab infu-
sion (Table 3). Hb recovered from 73 g/L (RR 115–145) to
128 g/L (RR 115–145), and the white cell count also im-
proved from 2.78 × 10^9/L (RR 5.0–15.0) to 7.83 × 10^9/L
(RR 5.0–15.0) (Table 3). At follow-up eight months
after ofatumumab infusion, there are no adverse events
reported.
A similar story gradually evolved in II-1. Although the
symptoms (thrombocytopenia, rash, and alopecia) initially
responded to a first course of rituximab (2 infusions of
750 mg/m2, on day 1 and 15), return of these symptoms,
plus increasing lethargy and night sweats within a year indi-
cated the need for retreatment. During the second of two
planned rituximab infusions, she developed severe diffuse
cutaneous erythema and tachycardia necessitating infusion
discontinuation, although again she still adequately B cell
depleted and had symptomatic relief for 32 months. She
then re-presented with platelets of 5 × 109/L, and thus re-
ceived ofatumumab (same dose as for patient II-2) without
incident. Her platelet count rapidly rose to 209 × 109/L,
with sustained therapeutic response and B cell depletion
(CD19 0.0%) now 8 months later. At follow-up, the cutane-
ous symptoms had resolved in both II-1 and II-2 although
the scarring alopecia is more likely to be chronic. The
hepatosplenomegaly, lethargy and night sweats had also
resolved. II -2 has kidney involvement that is likely to be
chronic. In terms of the serological response, anti-dsDNA
antibodies was 66 IU/ml (RR 0–9.9) at the time of relapse
and this dropped to 16 IU/ml (RR 0–9.9) eight months
after ofatumumab infusion (Table 3). Hb improved from
102 g/L (RR 115–145) to 118 g/L (RR 115–145) (Table 3).
At follow-up eight months after ofatumumab infusion,
there are no adverse events reported.
II-3 developed symptoms at age 26 months: facial rash,
alopecia, and platelets 6 × 109/L. He required IV methyl-
prednisolone, IVIG 2 g/Kg, and two infusions of rituximab
which he received without incident and with sustained
efficacy at last follow-up despite return of B cells (CD19
0.1% post rituximab; 9.4%) 8 months after receiving
rituximab.
Discussion and conclusions
This report emphasises a number of novel observations:
firstly, severe recalcitrant thrombocytopenia is a promin-
ent feature of PKCδ deficiency; secondly, we provide the
first description of acute TIN associated with PKCδ defi-
ciency; thirdly, PKCδ deficiency is exquisitely sensitive to
B cell depletion (with no obvious difference in efficacy
between rituximab or Ofatumumab, notwithstanding the
issues of hypersensitivity); and lastly, 2 of the siblings
suffered intolerable infusion reactions to rituximab, but
have so far responded well to ofatumumab, which may
offer a less immunogenic alternative for patients with
prior rituximab hypersensitivity.
PKCδ has been ascribed critical roles in the regulation
of cellular proliferation and apoptosis, with important
pro-apoptotic activity due to the inhibition of cell cycle
progression [7]. PKCδ-driven apoptosis has also been re-
ported in association with various DNA damaging agents,
such as UV radiation and etoposide [6, 8, 9]. PKCδ regu-
lates B cell negative selection, and deficiency of PKCδ
causes systemic autoimmunity in mice [10], and also in
humans with phenotypes that include lymphoproliferative
disease and lupus-like autoimmunity [4, 11]. Belot et al.
described 3 siblings from a consanguineous kindred with
an increased number of immature B cells and a develop-
mental shift towards naïve B cells with an immature
phenotype, indicating that PKCδ is vital in regulating B
cell maturation and tolerance [11], (and see Table 4).
These observations almost certainly explain why auto-
immunity in humans caused by PKCδ deficiency seems
particularly amenable to treatments that target B lympho-
cytes, as illustrated by the kindred described herein.
Ofatumumab is a fully human monoclonal antibody
targeting B cells that may provide an attractive alterna-
tive to rituximab since it can deplete rituximab-resistant
cells that express low levels of CD20, possibly through
targeting a different epitope of CD20 [12], or by increased
complement-dependent cytotoxicity [13]. The first ofatu-
mumab clinical trial in 2008 was in patients with refractory
or relapsed chronic lymphocytic leukaemia, leading to
Federal Drug Agency approval for this indication in
2009. Ofatumumab has since been used for various condi-
tions including nephrotic syndrome, refractory follicular
lymphoma, and multiple sclerosis [14–16], amongst others.
Several trials have highlighted a potential role for ofatumu-
mab in diseases that are refractory to conventional treat-
ment. For example, in biological-naïve rheumatoid arthritis
with an inadequate response to methotrexate, patients on
ofatumumab had significantly improved clinical outcomes
without detectable immunogenicity [17]. In comparison to
rituximab, which is a chimeric antibody, ofatumumab is a
fully humanised monoclonal antibody (generated via hu-
man immunoglobulin transgenic mice) which may explain
this reduced immunogenicity, and perhaps why this was
better tolerated than rituximab in our two patients.
Although rituximab did not demonstrate efficacy in
clinical trials of patients with SLE (probably due to trial
methodological considerations), there is an increasingly
compelling real-world evidence base for the efficacy of B
cell depletion with rituximab in patients with refractory
SLE [18]. That said, severe infusion reactions are com-
monly reported and therefore alternative B cell depleting
agents may be required. The first report of ofatumumab
in SLE was in an adult in 2014 [19]; in addition, there
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has been a single report of its use in jSLE, where it was
used successfully to treat a 20 year old with recalcitrant
life-threatening autoimmune haemolytic anaemia (AIHA)
[20]. This patient had also failed multiple drugs, and had
also experienced a severe infusion reaction to rituximab
[20]. The dose we used (300 mg/1.73m2 on day 1; 700 mg/
1.73m2on day 15) was the same low-dose protocol as de-
scribed by Bonnani [21] for nephrotic syndrome, but lower
than that previously used in other reports for idiopathic
nephrotic syndrome [22]. Both II-1 and II-2 have had an
improvement in their symptoms following ofatumumab, in-
cluding improvement (but not normalisation) of renal func-
tion in II-2.
The main limitations of our observations thus far are
limited time to follow-up; and lack of detailed B cell
immunophenotyping pre and post B cell depletion, since
samples were not available to us for these studies. We
anticipate an ongoing relapsing disease course with return
of B cells. Therapeutic options beyond B cell depletion are
extremely limited, although there could be a role for other
B cell-targeting biologics. Ultimately, however, allogeneic
haematopoietic stem cell transplantation may be required,
although this has never been reported for PKCδ deficiency
(Table 4). Autologous HSCT, although potentially less
toxic than allogeneic and emerging as a possible treatment
for severe SLE [23, 24], is unlikely to be a useful thera-
peutic option for this monogenic form of SLE.
In conclusion, we describe the first favourable report
of the use of ofatumumab for the treatment of mono-
genic lupus caused by PKCδ deficiency. Ofatumumab
could also have a role for sporadic jSLE patients intoler-
ant of rituximab.
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